Author

Eva E. Waltl

Observed names: E. E. Waltl, EE Waltl, Eva E Waltl, Eva Waltl

Observed institutions: MorphoSys (Germany), Medical University of Vienna

OpenAlex ID: A5091035067

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

2019 · Julia Eckl-Dorna, Milena Weber, et al. · EBioMedicine · 43

PDF

Localization of the human neonatal Fc receptor (FcRn) in human nasal epithelium

2015 · Sara Heidl, Isabella Ellinger, et al. · PROTOPLASMA · 35

Betamethasone prevents human rhinovirus- and cigarette smoke- induced loss of respiratory epithelial barrier function

2018 · Eva E. Waltl, Regina Selb, et al. · Scientific Reports · 29

PDF

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

2022 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Clinical Cancer Research · 28

PDF

Infection with Rhinovirus Facilitates Allergen Penetration Across a Respiratory Epithelial Cell Layer

2015 · Katharina Gangl, Eva E. Waltl, et al. · International Archives of Allergy and Immunology · 26

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

2023 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Annals of Hematology · 23

Fish-derived low molecular weight components modify bronchial epithelial barrier properties and release of pro-inflammatory cytokines

2019 · Tanja Kalic, Isabella Ellinger, et al. · Molecular Immunology · 9

PDF

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2021 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Blood · 8

ELISA-Based Assay for Studying Major and Minor Group Rhinovirus–Receptor Interactions

2020 · Petra Pazderova, Eva E. Waltl, et al. · Vaccines · 6

PDF

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

2023 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Annals of Hematology · 3

PDF

Antibody Conjugates Bispecific for Pollen Allergens and ICAM-1 with Potential to Prevent Epithelial Allergen Transmigration and Rhinovirus Infection

2023 · Christina Weichwald, Ines Zettl, et al. · International Journal of Molecular Sciences · 3

PDF

Poster: ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

2021 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Primary Nasal Epithelial Cells From Allergic and Non-allergic Individuals Show Comparable Barrier Function

2020 · Eva E. Waltl, Victoria Stanek, et al. · Allergy Asthma and Immunology Research · 2

PDF

6th International Symposium on Molecular Allergology (ISMA)

2016 · Christiane Hilger, Kyra Swiontek, et al. · Clinical and Translational Allergy · 2

PDF

Establishment of a cell culture model based on primary epithelial cells to investigate damage and repair of respiratory epithelial cells

2015 · Eva E. Waltl, Regina Maria Selb, et al. · World Allergy Organization Journal · 2

ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

2021 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Characterisation and culture of primary human nasal epithelial cells and the influence of Interferon-gamma

2014 · Eva Waltl, Julia Eckl-Dorna, et al. · Clinical and Translational Allergy · 1

PDF

Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study

2025 · Anthea Peters, Grzegorz S Nowakowski, et al. · The Oncologist

PDF

Data from Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study